Literature DB >> 7998991

Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations.

M C Blatter Garin1, C Abbott, S Messmer, M Mackness, P Durrington, D Pometta, R W James.   

Abstract

Paraoxonase is a serum protein bound to high-density lipoproteins (HDLs). The physiological function of the enzyme is unknown, but a role in lipid metabolism has been postulated. To date, studies of the protein have had to rely on measurements of enzyme activity with various substrates. We have developed a highly specific, competitive e.l.i.s.a. using a previously characterized monoclonal antibody. The assay can detect 20 ng of paraoxonase with a working range of 75-600 ng. Intra- and interassay coefficients of variation were 6.5 and 7.9% respectively. Serum concentrations of paraoxonase in healthy subjects from Geneva and Manchester ranged from 25 to 118 micrograms/ml. There were significant differences in mean concentrations between the two groups (Geneva, 79.3 +/- 18.7 micrograms/ml; Manchester, 59.9 +/- 24.1 micrograms/ml: P < 0.001), differences also apparent when subjects were compared according to paraoxonase phenotype. These appeared to be largely a consequence of differences in apolipoprotein A-I concentrations between the two populations, suggesting that HDL particle number may be important in determining serum levels of paraoxonase. Paraoxonase specific activities were also significantly different between the two groups of subjects (Geneva, 2.08 +/- 0.96 units/mg; Manchester, 3.08 +/- 1.73 units/mg: P < 0.001), which may reflect differences in HDL particle composition. The e.l.i.s.a. should furnish the necessary complement to studies of paraoxonase enzymic activity and has already provided evidence for differences with respect to serum levels of the protein both between populations and between phenotypes within populations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998991      PMCID: PMC1137527          DOI: 10.1042/bj3040549

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Is paraoxon hydrolytic activity in serum predictive of myocardial infarction?

Authors:  F Szabó; K Róna; A Czinner; B Gachályi; A Káldor
Journal:  Clin Chem       Date:  1987-05       Impact factor: 8.327

Review 2.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  B N La Du
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

3.  Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins.

Authors:  A Steinmetz; C Jakobs; S Motzny; H Kaffarnik
Journal:  Arteriosclerosis       Date:  1989 May-Jun

4.  Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations.

Authors:  R W James; D Pometta
Journal:  Atherosclerosis       Date:  1990-07       Impact factor: 5.162

5.  'A'-esterases. Enzymes looking for a role?

Authors:  M I Mackness
Journal:  Biochem Pharmacol       Date:  1989-02-01       Impact factor: 5.858

6.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.

Authors:  K N Gan; A Smolen; H W Eckerson; B N La Du
Journal:  Drug Metab Dispos       Date:  1991 Jan-Feb       Impact factor: 3.922

7.  Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects.

Authors:  R W James; D Pometta
Journal:  Diabetes       Date:  1990-10       Impact factor: 9.461

8.  Low A-esterase activity in serum of patients with fish-eye disease.

Authors:  M I Mackness; C H Walker; L A Carlson
Journal:  Clin Chem       Date:  1987-04       Impact factor: 8.327

9.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction.

Authors:  J McElveen; M I Mackness; C M Colley; T Peard; S Warner; C H Walker
Journal:  Clin Chem       Date:  1986-04       Impact factor: 8.327

10.  Absence of "A"-esterase activity in the serum of a patient with Tangier disease.

Authors:  M I Mackness; E Peuchant; M F Dumon; C H Walker; M Clerc
Journal:  Clin Biochem       Date:  1989-12       Impact factor: 3.281

View more
  16 in total

1.  Paraoxonase-1 and clopidogrel efficacy.

Authors:  Jordi Camps; Jorge Joven; Bharti Mackness; Michael Mackness; Dan Tawfik; Dragomir Draganov; Lucio G Costa; György Paragh; Ildikó Seres; Sven Horke; Richard James; Antonio Hernández; Srinivasa Reddy; Diana Shih; Mohamed Navab; Daniel Rochu; Michael Aviram
Journal:  Nat Med       Date:  2011-09-07       Impact factor: 53.440

2.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

3.  The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

Authors:  V Ancrenaz; J Desmeules; R James; P Fontana; J-L Reny; P Dayer; Y Daali
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

4.  Smoking is associated with reduced serum paraoxonase, antioxidants and increased oxidative stress in normolipidaemic acute myocardial infarct patients.

Authors:  Arun Kumar; Utpal Kumar Biswas
Journal:  Heart Asia       Date:  2011-01-01

5.  Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

Authors:  L W Castellani; M Navab; B J Van Lenten; C C Hedrick; S Y Hama; A M Goto; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

6.  Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

7.  Determinants of variation in human serum paraoxonase activity.

Authors:  D L Rainwater; S Rutherford; T D Dyer; E D Rainwater; S A Cole; J L Vandeberg; L Almasy; J Blangero; J W Maccluer; M C Mahaney
Journal:  Heredity (Edinb)       Date:  2008-10-29       Impact factor: 3.821

8.  Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.

Authors:  D M Shih; L Gu; S Hama; Y R Xia; M Navab; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

9.  Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.

Authors:  Sara Deakin; Ilia Leviev; Marie-Claude Brulhart-Meynet; Richard W James
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

10.  Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study.

Authors:  Rakesh S Birjmohun; Menno Vergeer; Erik S G Stroes; Manjinder S Sandhu; Sally L Ricketts; Michael W Tanck; Nicholas J Wareham; J Wouter Jukema; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.